Prostate Cancer, Advanced or Metastatic - Changes to This Summary (07 / 02 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made to this summary.
Prostate Cancer - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Prostate Cancer - Selenium
OverviewThis section contains the following key information:Soy foods (e.g., soy milk, miso, tofu, and soy flour) contain phytochemicals that may have health benefits and, among these, soy isoflavones have been the focus of most of the research.Soy isoflavones are phytoestrogens. The major isoflavones in soybeans are genistein (the most abundant), daidzein, and glycitein.Genistein affects components of multiple growth and proliferation -related pathways in prostate cancer cells, including the COX-2 /prostaglandin, epidermal growth factor (EGF), and insulin-like growth factor (IGF) pathways.Some preclinical studies have indicated that the combined effect of multiple isoflavones may be greater than that of a single isoflavone.Some animal studies have demonstrated prostate cancer prevention effects with soy and genistein; however, other animal studies have yielded conflicting results regarding beneficial effects of genistein on prostate cancer metastasis.Epidemiologic studies
Prostate Cancer - Soy
OverviewZyflamend is a dietary supplement that contains extracts of rosemary, turmeric, ginger, holy basil, green tea, hu zhang, Chinese goldthread, barberry, oregano, and Baikal skullcap.The individual components of Zyflamend have anti-inflammatory and possible anticarcinogenic properties.In various preclinical studies, Zyflamend has been shown to suppress the expression of certain genes involved in the inflammatory response and in cancer progression, such as cyclooxygenase 1(COX-1), COX-2, 5-lipoxygenase (5-LOX), and 12-LOX.In other preclinical studies, Zyflamend has demonstrated single-agent anticancer activity, and the capacity to be combined with hormonal and chemotherapy agents for improved cancer suppression.Results of a phase I study of Zyflamend suggest that use of this supplement is not associated with serious toxicity or adverse effects.General Information and HistoryZyflamend is a dietary supplement that contains extracts of rosemary, turmeric, ginger, holy
Prostate Cancer - Changes to This Summary (02 / 27 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Prostate Cancer - Changes to This Summary (04 / 11 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Treatment Option Overview for Prostate CancerAdded text to state that in a registry of men with rising prostate-specific antigen (PSA) after initial treatment of clinically localized prostate cancer, 19 of 510 men who had undergone radical prostatectomy complained of reduced penile size; however, the data were based upon physician reporting of patients' complaints rather than direct patient questioning or before-and-after measurement of penile length (cited Parekh et al. as reference 51). Added text to state that the use of androgen deprivation therapy may be associated with complaints of penile shortening, although the data are very limited. Also added text to state that in a registry study of men with rising PSA after initial treatment of clinically localized prostate cancer treated with
Prostate Cancer - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of prostate cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in
Prostate Cancer - Changes to This Summary (10 / 10 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.LycopeneAdded text about a 2013 meta-analysis, including four of five cohort studies from a 2004 meta-analysis, two new meta-analyses, and three case-control studies from the previous study plus eight new ones, that reported less convincing evidence for risk reduction; the authors concluded that tomatoes may play a modest role in the prevention of prostate cancer (cited Chen et al. as reference 26).SoyAdded text about an updated 2013 meta-analysis that confirmed the good safety profiles of isoflavones but indicated no significant differences between treated and control groups for prostate-specific antigen (PSA) levels or sex steroid endpoints (cited van Die et al. as reference 22).Added text to state that another group conducted a randomized placebo-controlled trial to examine the effect of soy
Prostate Cancer, Advanced or Metastatic - Questions and Answers About Vitamin E
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Prostate Cancer, Advanced or Metastatic - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.